Immune-Checkpoint Inhibitor Use in Patients with Cancer and Pre-Existing Autoimmune Diseases

Evidence is accumulating with regard to the use of ICIs in this ‘at-risk’ population, with retrospective data suggesting that they have an acceptable safety profile, but that there is a risk of disease flare or other immune-related adverse events occurrence.